Table 2 Main baseline features in the eight patients meeting ASAS criteria [32] for peripheral spondyloarthritis
Patient 14 | Patient 15 | Patient 16 | Patient 17 | Patient 18 | Patient 19 | Patient 20 | Patient 21 | |
|---|---|---|---|---|---|---|---|---|
Type of SpA | AS | AS | AS | AS | uSpA | uSpA | PsA | PsA |
Sacroiliitis | Grade 2 | Grade 3 | Grade 3 | Grade 3 | Grade 0 | Grade 1 | Grade 0 | Grade 0 |
HLA-B27 | + | - | + | + | + | + | - | - |
Gender | Male | Female | Male | Female | Female | Female | Female | Female |
Disease duration (years) | 8 | 15 | 19 | 6 | 10 | 10 | 10 | 20 |
Main articular and extraarticular symptoms | Coxitis, arthritis | Arthritis | Arthritis, uveitis | Peripheral enthesitis (Achilles tendon, knee, elbow), arthritis, chest pain | Arthritis | Arthritis, IBD, uveitis | Arthritis, dactylitis, psoriasis, uveitis | Arthritis, psoriasis |
Concomitant NSAIDs/steroids (dosage) | Yes/no | No/yes (20 mg/day) | Yes/yes (5 mg/day) | Yes/yes (15 mg/day) | Yes/yes (8 mg/day) | No/yes (10 mg/day) | Yes/yes (20 mg/day) | Yes/yes (20 mg/day) |
Concomitant DMARDs | Methotrexate | No | Methotrexate | Leflunomide | Methotrexate | Methotrexate | Methotrexate | Methotrexate |
Previous biologics other than anti-TNF | No | Anakinra | No | Abatacept | No | No | No | No |